Abstract
In this prospective randomized study of initial chemotherapy for advanced measurable metastatic large bowel carcinoma, the response rate was 6/32 (19%) for FU + HU and 5/32 (16%) for MOF-Strep; the estimated median survival is 43 weeks for both treatments. Patients who received MOF-Strep experienced substantially greater vomiting and hematologic toxicity than patients who received FU + HU (p less than 0.001).
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / toxicity
-
Colonic Neoplasms / drug therapy*
-
Drug Evaluation
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / toxicity
-
Humans
-
Hydroxyurea / administration & dosage
-
Hydroxyurea / toxicity
-
Kidney Diseases / chemically induced
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Prospective Studies
-
Random Allocation
-
Rectal Neoplasms / drug therapy*
-
Semustine / administration & dosage
-
Semustine / toxicity
-
Streptozocin / administration & dosage
-
Streptozocin / toxicity
-
Vincristine / administration & dosage
-
Vincristine / toxicity
-
Vomiting / chemically induced
Substances
-
Semustine
-
Vincristine
-
Streptozocin
-
Fluorouracil
-
Hydroxyurea